STOCK TITAN

Nasus Pharma appoints Nir Sassi as new CFO

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Nasus Pharma Ltd. (NSRX) appointed Nir Sassi as chief financial officer, effective November 11, 2026, and entered into an employment agreement with him dated that day. The company expects to enter its standard-form indemnification agreement with Sassi on the same terms as agreements with its directors and executive officers.

Sassi brings nearly 25 years of finance experience and most recently served as CFO of Indaptus Therapeutics from August 2021 to April 2026. Nasus plans to initiate the NS002 pivotal clinical Phase 3 study in the fourth quarter of 2026 and have a topline data readout in the first quarter of 2027.

Finance experience Nearly 25 years Sassi's experience in public company finance, capital markets, and biopharmaceutical operations.
Planned NS002 Phase 3 study initiation Fourth quarter of 2026 The company plans to initiate the pivotal clinical study.
Planned NS002 topline data readout First quarter of 2027 The company plans to have a topline data readout from the study.
pivotal clinical Phase 3 study medical
"progress NS002 toward a pivotal clinical Phase 3 study"
topline data readout medical
"a topline data readout in the first quarter of 2027"
A topline data readout is the initial summary of a clinical trial’s most important results, showing whether the study met its main goals. Like a headline score after a sports game, it gives investors a quick sense of success or failure that can shift a company’s outlook, affect future funding, and move the stock while more detailed analyses and regulatory reviews follow.
intranasal powder technology platform technical
"through its proprietary intranasal powder technology platform"
anaphylaxis medical
"Type I allergic reactions, including anaphylaxis"
Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new CFO of NSRX?

Nir Sassi was appointed chief financial officer effective November 11, 2026. Nasus Pharma entered into an employment agreement with him dated that day.

When does NSRX plan to start the NS002 Phase 3 study and report data?

Nasus plans to initiate the pivotal clinical Phase 3 study in the fourth quarter of 2026 and have a topline data readout in the first quarter of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-42796

 

Nasus Pharma Ltd.

 

P.O. Box 284

Tel Aviv, Israel 6100201

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 
 

 

CONTENTS

 

Appointment of Chief Financial Officer

 

On November 11, 2026, Nasus Pharma Ltd. (the “Company”) appointed Mr. Nir Sassi as the Company’s Chief Financial Officer (“CFO”). In connection with Mr. Sassi’s appointment as CFO, the Company entered into an Employment Agreement, dated as of November 11, 2026, by and between the Company and Mr. Sassi.

 

In connection with this appointment, the Company expects to enter into its standard form of indemnification agreement with Mr. Sassi on the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. There are no related party transactions involving Mr. Sassi required to be disclosed under Item 7.B of Form 20-F.

 

Prior to joining the Company Mr. Sassi served as Chief Financial Officer of Indaptus Therapeutics, Inc. (Nasdaq: INDP) from August 2021 to April 2026. Before that, Mr. Sassi served as Chief Financial Officer of Intec Pharma Ltd. (formerly Nasdaq: NTEC) following his service as a Senior Manager at PricewaterhouseCoopers Israel. Mr. Sassi holds a bachelor’s degree in economics and accounting from Ben-Gurion University of the Negev, Israel, and is a certified public accountant in Israel.

 

Press Release

 

On November 16, 2026, the Company issued a press release titled “Nasus Pharma Appoints Nir Sassi as Chief Financial Officer,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

 

Incorporation By Reference

 

This Report of Foreign Private Issuer on Form 6-K (excluding the second, third and fifth paragraphs of the press release included as Exhibit 99.1 hereto) is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-298693) and Form S-8 (File Nos. 333-299524 and 333-296252), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release issued on November 16, 2026 by Nasus Pharma Ltd. titled “Nasus Pharma Appoints Nir Sassi as Chief Financial Officer”

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NASUS PHARMA LTD.
     
Date: November 16, 2026 By: /s/ Brendan O’Grady
  Name:  Brendan O’Grady
  Title: Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

 

Nasus Pharma Appoints Nir Sassi as Chief Financial Officer

 

Seasoned Biopharmaceutical Finance Executive Brings Nearly 25 Years of Experience in Capital Markets, Corporate Finance and Public Company Leadership

 

TEL AVIV, Israel, November 16, 2026, (GLOBE NEWSWIRE) – Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of Mr. Nir Sassi as Chief Financial Officer, effective November 11, 2026. Mr. Sassi brings nearly 25 years of experience in public company finance, capital markets, and biopharmaceutical operations to Nasus Pharma, and has served as chief financial officer of two Nasdaq-listed biopharmaceutical companies.

 

“We are delighted to welcome Nir to Nasus Pharma,” said Udi Gilboa, Chairman of the Board of Directors of Nasus Pharma. “Nir brings a wealth of financial leadership experience, a strong track record in the capital markets, and a deep understanding of the biopharmaceutical industry. His expertise and perspective will be particularly valuable as Nasus enters an important phase of its development, and I am confident he will be a strong addition to our leadership team.”

 

“Nir joins us at an important time as we prepare to initiate our planned NS002 pivotal study and finalize our pre-commercial plans,” said Brendan O’Grady, Chief Executive Officer of Nasus Pharma. “His record of financial and operational management for biopharmaceutical companies will provide us with important support as we progress NS002 toward a pivotal clinical Phase 3 study in the fourth quarter of 2026 and a topline data readout in the first quarter of 2027. I look forward to working with Nir as we advance NS002 and our Nasax® platform programs toward their full clinical and commercial potential.”

 

Mr. Sassi most recently served as Chief Financial Officer of Indaptus Therapeutics, Inc., a Nasdaq-listed clinical-stage biopharmaceutical company, where he oversaw its financial operations, strategic financial planning, and capital markets activities. Previously, he served as Chief Financial Officer of Intec Pharma Ltd. and began his professional career at PwC. Mr. Sassi holds a B.A. in Economics and Accounting from Ben-Gurion University of the Negev and is a Certified Public Accountant in Israel.

 

“I am excited to join Nasus Pharma at this stage of the Company’s development,” said Mr. Sassi. “NS002 has the potential to offer patients and caregivers an intranasal alternative to injectable epinephrine for severe allergic reactions, and the Nasax® platform supports a growing pipeline of intranasal product candidates across multiple therapeutic areas. I look forward to working with Brendan, Udi, and the entire Nasus Pharma team to support disciplined execution and to build long-term value for our shareholders.”

 

The Company plans to initiate its pivotal clinical Phase 3 study in the fourth quarter of 2026 and have a topline data readout from that study in the first quarter of 2027.

 

Additional information regarding Mr. Sassi’s appointment will be furnished by the Company in a Report of Foreign Private Issuer on Form 6-K with the U.S. Securities and Exchange Commission (the “SEC”).

 

 
 

 

About Nasus Pharma Ltd.

 

Nasus Pharma Ltd. (NYSE American: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding: the Company’s expectations regarding its growth, the advancement of its clinical programs, and anticipated clinical and commercial milestones; the planned timing of the planned NS002 pivotal clinical Phase 3 study and topline data readout the Company’s plans to strengthen its financial and operational capabilities and build its leadership team; that Mr. Sassi’s experience will prove highly valuable to the Company; the significant opportunity of the Company’s intranasal drug delivery platform and its ability to bring innovative drug delivery products to patients and address significant unmet medical needs; and the Company’s beliefs about the impact of its leadership additions, including the appointment of Mr. Sassi, on its long-term growth and execution of its corporate strategy. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These risks include, among others, risks relating to regulatory interactions and alignment, the timing and outcome of the planned NS002 pivotal clinical Phase 3 study, topline data readout, clinical-trial results, regulatory approval, the Company’s ability to obtain additional financing, and the development and implementation of pre-commercial and commercial plans. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the SEC on March 25, 2026 and in the Company’s subsequent filings and reports furnished to the SEC. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

 

Corporate Contact

 

Nasus Pharma Ltd. Israel

info@nasuspharma.com

 

Investors Contact

 

Mike Moyer

LifeSci Advisors

+1-617-308-4306

mmoyer@lifesciadvisors.com

 

 

 

Filing Exhibits & Attachments

2 documents

Keep reading